<DOC>
	<DOCNO>NCT02748135</DOCNO>
	<brief_summary>The purpose study assess safety tolerability profile TB-403 ( humanize monoclonal antibody placental growth factor ( PlGF ) ) pediatric subject relapse refractory Medulloblastoma .</brief_summary>
	<brief_title>A Two-Part Study TB-403 Pediatric Subjects With Relapsed Refractory Medulloblastoma</brief_title>
	<detailed_description>The study conduct 2 part . In part A , maximum tolerate dose TB-403 determine pediatric subject relapse refractory Medulloblastoma ( MB ) well Neuroblastoma ( NB ) , Ewing Sarcoma ( ES ) Alveolar Rhabdomyosarcoma ( ARMS ) . In part B clinical trial , safety tolerability TB-403 maximum tolerate dose evaluate pediatric subject relapse refractory Medulloblastoma .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma , Alveolar</mesh_term>
	<criteria>1 . Provide write informed consent ( Subject legal representative ) 2 . Be &gt; 6 month &lt; 18 year age 3 . Have histologicallyconfirmed diagnosis MB , NB , ES , ARMS 4 . Have document relapse refractoriness least 1 line ( MB ARMS subject ) 2 line ( NB ES subject ) standardofcare therapy , include follow : Surgery , unless document contraindication Radiotherapy , unless document contraindication Chemotherapy , unless document contraindication 5 . Have undergone magnetic resonance imaging ( MRI ) MB , computerize tomography ( CT ) / metaiodobenzylguanidine ( MIBG ) scan NB , CT / magnetic resonance imaging ( MRI ) ES ARMS within 1 month prior first dose study treatment 6 . Have Lansky score ≥ 40 subject 16 year age Karnofsky score ≥ 40 subject 16 year age &lt; 18 year 7 . Have adequate organ function , define : Peripheral absolute neutrophil count ≥ 1.5 × 10^9/L Platelet count ≥ 100 × 10^9/L Hemoglobin ≥ 8mg/dL ( transfusion reach level permit ) International normalize ratio ( INR ) &lt; 1.5 ; partial thromboplastin time ( PTT ) &lt; 1.5 upper limit normal ( ULN ) ; ddimer &lt; 250ng/mL Serum creatinine ≤ specify maximum value base age describe : 6 month 3 year age : serum creatinine ≤ 0.4mg/dL 3 13 year age : serum creatinine ≤ 0.7mg/dL &gt; 13 year age : serum creatinine ≤ 1mg/dL Creatinine clearance &gt; 50mL/min Serum aspartate aminotransferase ( AST ) serum alanine aminotransferase ( ALT ) &lt; 2.5 × ULN ; serum bilirubin &lt; 1.5 × ULN 8 . Have symptoms cranial hypertension convulsion within 14 day Cycle 1 Day 1 ( antiepileptic drug corticoid allow control preexist symptom ) 9 . If female child bear potential , must lactate must negative pregnancy test ( blood urine , discretion investigator ) prior enrollment use effective contraception study participation . Women continue effective contraception 3 month follow last dose TB403 . 10 . If sexuallyactive male , must agree use latex condom sexual contact female child bear potential participating study 3 month follow last dose TB403 . 11 . For subject corticosteroid endocrine deficiency tumorassociated symptom , must stable ( decrease ) dose least 7 day first dose study treatment . 1 . Have clinically significant disease consider investigator interfere study participation 2 . Have fully recover acute toxic effect prior anticancer therapy ( e.g. , chemotherapy , immunotherapy , radiation therapy ) currently receive cytotoxic chemotherapy , immunotherapy radiation therapy . A minimum period 4 week / 28 day require end prior anticancer therapy initiation TB403 . 3 . Have cancer MB , NB , ES RMS Part A study cancer MB previous 5 year Parts A B 4 . Have participate another therapeutic clinical trial investigational drug within 1 month 5 . Have know active uncontrolled infection 6 . Have major surgery bone fracture within 28 day first dose study treatment 7 . Have previously receive TB403 8 . Have history severe allergic anaphylactic reaction hypersensitivity recombinant proteins excipients investigational drug 9 . Are receive increase dos corticosteroid 10 . Are eligible curative treatment option . 11 . Have prior thrombotic event ( e.g. , pulmonary embolism , deep vein thrombosis ) currently receive therapeutic prophylactic dos anticoagulant .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>